Under the conventional method of toxicity studies, large libraries are screened in search of potential drug candidates. This method is expensive, resource- and time-consuming, and has a low success rate. Consequently, high content screening (HCS) solutions for testing the potential toxicity of chemicals and complex substances are being adopted by pharmaceutical companies to improve in-vitro toxicity testing by reducing the time and cost.

  • The need for cost containment in pharmaceutical R&D, advancements in informatics solutions and imaging instruments, and government funding and venture capital investments across developed markets are the major factors driving the growth of the high-content screening (HCS) market.
  • The increasing number of contract research organizations providing HCS outsourcing services and the application of HCS in personalized medicine present significant growth opportunities in the market.

Key Market Trends

Instrument Segment is Expected to Lead the Market Over the Forecast Period

Based on the product segment, the high content screening market is further segmented into instruments, consumables, and software and services. Among all high content screening products, the instrument segment occupies the largest share of the market. The large share of this segment is attributed to advances in instrumentation and automation techniques and high prices of HCS instruments. Companies are developing automated solutions such as instruments with advanced visualization capability, in line with enhanced software platform. These advances are boosting the market growth. In January 2017, PerkinElmer Inc. launched the Vectra Polaris automated quantitative pathology imaging system. This multi-modal tissue imaging system enables researchers to gain a deeper level of understanding of disease mechanisms related to new cancer immunotherapy approaches. The increasing funds for product development and increasing use of the instruments are boosting the segment.

Asia-Pacific Region is Expected to Attain the Highest Growth Rate Over the Forecast Period

The high content screening market in Asia-Pacific is expected to register the highest CAGR over the forecast period. Factors, such as increasing drug discovery research, government initiatives, growing focus of multinational companies on emerging markets, and developing R&D infrastructure, are driving the growth of the HCS market in this region. Japan and China are expected to witness significant growth during the forecast period, as many research and development programs are been carried out by the manufacturers to improve the cell analyzers and flow cytometers in the high content screening market.

Competitive Landscape

For compound profiling applications, many pharmaceutical companies are partnering with contract research organizations to identify potential candidates for drug discovery. The HCS market is highly competitive in nature. The majority of large global players are based out of the United States and these players have expertise in other biotechnology/medical-technology verticals as well, which helps them in controlling the major market share, through a presence in the allied markets.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support